Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease [3]

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 171-

  Boulanger, Emmanuelle ^a   Meignin, V ^a   Leverger, G ^b   Solal Celigny P ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c CENTRE JEAN BERNARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADOLESCENT; B LYMPHOCYTE; CASE REPORT; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LYMPH NODE BIOPSY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SPLENECTOMY; SPLENOMEGALY;

EID: 12244287907     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg012     Document Type: Letter

References (5)

1. Diehl V, Sextro M, Franklin J et al. Clinical presentation, course and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1999; 17: 776-783.
2. Kirchner EM, Ebsen M, Kirchner J et al. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after rituximab monotherapy. Ann Oncol 2001; 12: 1169-1171.
3. Keilholz U, Szelényi H, Siehl J et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti-CD20 monoclonal antibody) and interleukin-2. Leuk Lymphoma 1999; 35: 641-642.
4. Lush RJ, Jones SG, Haynes AP. Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: long-term follow-up of allografting and monoclonal antibody therapy. Br J Haematol 2001; 114: 734-735.
5. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.